A drug delivery device for administering a drug at a controlled rate for a prolonged period of time to produce a local or systemic physiological or pharmacological effect is comprised of a wall surrounding a reservoir containing a drug. The reservoir is formed of a solid drug carrier permeable to the passage of the drug. The wall is formed in at least a part of a microporous material the pores of which contain a drug release rate controlling medium also permeable to the passage of the drug, but the rate of passage of the drug through the medium is lower than the rate passage of the drug through the solid drug carrier so that drug release by the medium in the microporous wall is the drug release rate controlling step for releasing drug from the drug delivery device.
Ethosomes are soft, malleable vesicles and potential carrier for transportation of drugs.Ethosomes are characterized by simplicity in their preparation, safety and efficacy and can be tailored for enhanced skin permeation of active drugs. Ethosomes have been found to be much more efficient at delivering drug to the skin, than either liposomes or hydro alcoholic solution. Ethosomes have been tested to encapsulate hydrophilic drugs, cationic drugs, proteins and peptides. Ethosomal carrier opens new challenges and opportunities for the development of novel improved therapies.
Ocular drug delivery is one of the most fascinating and challenging tasks facing the Pharmaceutical researchers. One of the major barriers of ocular medication is to obtain and maintain a therapeutic level at the site of action for prolonged period of time. The eye as a portal for drug delivery is generally used for local therapy against systemic therapy to avoid the risk of eye damage from high blood concentration of the drug, which is not intended.
Clotrimazole is an antifungal drug for treatment of cutaneous candidiasis infections. However its oral administration is associated with number of drawbacks. The goal of the current investigation is to evaluate the transdermal potential of novel vesicular carrier, ethosomes, bearing Clotrimazole an antifungal having limited transdermal permeation. Clotrimazole loaded ethosomes were prepared, optimized and characterized for vesicular shape and surface morphology, vesicular size, size distribution, entrapment efficiency, and stability. The ethosomal formulation (E63 having 3%phospholipids content and 35% ethanol showing the greatest entrapment (58.75%). Stability study was performed for 120 days. Furthermore ethosomal delivery system could be considered for the treatment of number of dermal infections with better efficiency
Dithranol belongs to the keratolytic category, which is widely used drug in the treatment of psoriasis. The drug is practically insoluble in water. Many conventional dosage forms for psoriasis treatment have been have been formulated earlier, but they did not show good results. Hence in the present study, it was attempted to formulate dithranol in the form of solid lipid nanoparticle. Solid lipid nanoparticles of dithranol were obtained by adaption of lipid dispersion method. Preformulation studies were performed to check the compatibility of drug and excepient for the preparation of formulation by DSC and no interaction was found. Solubility study, partition coefficient determination, UV analysis, HPLC study, FTIR study were also performed. After the preformulation studies Dithranol loaded solid lipid nanoparticles was also prepared. Hence it was concluded that solid lipid nanoparticle of dithranol could be formulated.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.